Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.…
Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics (NASDAQ: TPST) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.2870 USD on 20 November 2026, down 97.0% over 52 weeks. Its 52-week range is 0.2803 USD to 10.33 USD: the price is 97.2% below the high and 2.4% above the low.
Its market capitalisation is 5.74M USD.
Tempest Therapeutics reports return on equity of -393.9% and an operating margin of 0.0%.
Its debt exceeds its cash by 6.36M USD, a debt-to-equity ratio of 1.22. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 30 March 2027.